Overview

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus Infection

Status:
Completed

Trial end date:
2015-09-28

Target enrollment:

Participant gender:

Summary

The primary objective of the study is to evaluate the safety and tolerability of voxilaprevir (formerly GS-9857) alone or with sofosbuvir (SOF)/velpatasvir (VEL) fixed dose combination (FDC) and antiviral activity of voxilaprevir in adults with genotype 1, 2, 3, 4 hepatitis C virus (HCV) infection. All participants will be monitored for up to 48 weeks after the last dose.

Phase:

Phase 1

Details

Lead Sponsor:

Gilead Sciences

Treatments:

Antiviral Agents
Molecular Mechanisms of Pharmacological Action